Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 6/20 | 0.57 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.51 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | MYC | P01106 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17572016 | 0.95 | PRMT5 (0.57) | NAMPTPRMT5HDAC6ENPP2ALDH1A1 | |
| SCHEMBL17560248 | 0.90 | PRMT5 (0.57) | NAMPTPRMT5HDAC6ALDH1A1KDM4E | |
| SCHEMBL1263315 | 0.88 | HDAC6 (0.67) | NAMPTPRMT5HDAC6HDAC8 | |
| SCHEMBL17560156 | 0.84 | NAMPT (0.58) | NAMPTPRMT5HDAC6ALDH1A1HDAC8 | |
| SCHEMBL13498396 | 0.84 | ENPP2 (0.47) | NAMPTPRMT5HDAC6ENPP2ALDH1A1 | |
| SCHEMBL1264708 | 0.82 | HDAC6 (0.63) | PRMT5HDAC6HDAC8 | |
| SCHEMBL4437418 | 0.82 | L3MBTL1 (0.49) | NAMPTPRMT5HDAC6ENPP2ALDH1A1 | |
| SCHEMBL17560153 | 0.81 | PRMT5 (0.56) | NAMPTPRMT5HDAC6ALDH1A1KDM4E | |
| SCHEMBL4431726 | 0.80 | HDAC6 (0.77) | NAMPTHDAC6ENPP2ALDH1A1KDM4E | |
| SCHEMBL17572220 | 0.78 | PRMT5 (0.50) | NAMPTPRMT5ALDH1A1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | AVILA THERAPEUTICS, INC. (US) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | ABCG2, CYP3A43, CYP3A5 | NAMPT 517/4885PRMT5 1868/4885HDAC6 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.